| Detected | Trial | Change |
|---|---|---|
| 2026-05-29 | NCT05144841 A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse… |
Trial completed |
| 2026-05-28 | NCT05562830 A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1)… |
date change Primary completion moved earlier: 2030-06-28 -> 2029-02-26 |
| 2026-05-28 | NCT05562830 A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1)… |
date change Completion moved earlier: 2030-06-28 -> 2029-02-26 |
| 2026-05-23 | NCT05139017 A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in… |
Trial sites expanded: 128 -> 131 locations |
| 2026-05-23 | NCT05458297 A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in… |
Primary endpoint(s) modified |
| 2026-05-23 | NCT05458297 A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in… |
Enrollment reduced: 223 -> 189 participants |
| 2026-05-23 | NCT05458297 A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in… |
Trial arms changed: 5 -> 4 |
| 2026-05-16 | NCT05139017 A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in… |
Trial sites expanded: 124 -> 128 locations |
| 2026-05-16 | NCT06717347 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus… |
Trial sites expanded: 253 -> 256 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06717347 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus… | Diffuse Large B-Cell Lymphoma | Recruiting |
| Phase 2/3 | |||
| NCT05139017 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in… | DLBCL | Recruiting |
| Phase 2 | |||
| NCT06890884 | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide… | Lymphoma, Large B-Cell, Diffuse | Recruiting |
| NCT05458297 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05562830 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1)… | Urothelial Carcinoma | Recruiting |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With… | B-cell Acute Lymphoblastic Leukemia | Recruiting |